Tenax Therapeutics, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Tenax Therapeutics, Inc. - overview
Established
1967
Location
Chapel Hill, NC, US
Primary Industry
Biotechnology
About
Tenax Therapeutics, Inc. , based in the US, specializes in developing innovative therapies for cardiopulmonary conditions, focusing on pulmonary hypertension and creating effective treatments to enhance patient outcomes. Founded in 1967 and headquartered in Chapel Hill, US, Tenax Therapeutics, Inc. is dedicated to advancing therapies for pulmonary hypertension.
The company has undergone strategic shifts to focus on its core mission of addressing severe cardiopulmonary diseases. The firm achieved its most recent funding through a PIPE round led by BVF Partners, which facilitated a significant capital influx for ongoing development. Tenax Therapeutics develops innovative cardiopulmonary therapies with a key focus on pulmonary hypertension. Their lead products, TNX-201 and TNX-103, aim to meet critical medical needs within the pulmonary hypertension market, addressing the lack of effective treatments for populations with low survival rates.
Their patient-centric approach entails precise medicine strategies and efficient clinical trials, primarily targeting healthcare providers across North America and Europe. Tenax Therapeutics' revenue is primarily derived from product sales of its proprietary therapies, TNX-201 and TNX-103, as they advance through clinical trials toward market approval. Sales transactions are typically made directly to hospitals and healthcare facilities, emphasizing the innovative nature of their products, which are positioned to improve patient survival and quality of life as they move through regulatory processes. In August 2024, Tenax Therapeutics, Inc.
secured USD 100 mn through a PIPE deal led by BVF Partners, among others, to enhance its development of phase 3 treatments for cardiovascular and pulmonary diseases. The investment will facilitate the launch of new products and expansion into additional markets, with a focus on increasing their presence in healthcare settings that address pulmonary hypertension treatment needs. The funding is set to bolster the company's research and development efforts, ensuring that new therapies reach the market effectively.
Current Investors
Venrock, Vivo Capital, Sphera Fund Management
Primary Industry
Biotechnology
Sub Industries
Biotechnology, Pharmaceutical Research & Development
Website
www.tenaxthera.com/
Company Stage
Mature - Growth Capital
Total Amount Raised
Subscriber access only
Tenax Therapeutics, Inc. - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| PIPE | Completed | Tenax Therapeutics, Inc. | - |
Displaying 1 - 1 of 1
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.